SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edn. Br. J. Pharmacol 164 (Suppl. 1): S1S324.
  • Amiri F, Virdis A, Neves MF, Iglarz M, Seidah NG, Touyz RM et al. (2004). Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 110: 22332240.
  • Andreis PG, Neri G, Tortorella C, Aragona F, Rossi GP, Nussdorfer GG (2002). Mechanisms transducing the aldosterone secretagogue signal of endothelins in the human adrenal cortex. Peptides 23: 561566.
  • Arima S (2006). Aldosterone and the kidney: rapid regulation of renal microcirculation. Steroids 71: 281285.
  • Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F et al. (2003). Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 14: 22552263.
  • Arima S, Kohagura K, Xu HL, Sugawara A, Uruno A, Satoh F et al. (2004). Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43: 352357.
  • Arrick DM, Mayhan WG (2010). Inhibition of endothelin-1 receptors improves impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type-1 diabetic rats. Microcirculation 17: 439445.
  • Austin RC, Lentz SR, Werstuck GH (2004). Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differ 11 (Suppl. 1): S56S64.
  • Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Lüscher TF (1998). ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 31 (Pt 2): 499504.
  • Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M et al. (2002). Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 39: 351358.
  • Bayorh MA, Rollins-Hairston A, Adijiah J, Lyn D, Eatman D (2011). Eplerenone suppresses aldosterone/salt-induced expression of NOX-4. J Renin Angiotensin Aldosterone Syst 12: 195201.
  • Black SM, Johengen MJ, Solfer SJ (1998). Coordinated regulation of genes of the nitric oxide and endothelin pathways during the development of pulmonary hypertension in fetal lambs. Pediatr Res 44: 821830.
  • Böhm F, Jensen J, Svane B, Settergren M, Pernow J (2008). Intracoronary endothelin receptor blockade improves endothelial function in patients with coronary artery disease. Can J Physiol Pharmacol 86: 745751.
  • Bourque SL, Davidge ST, Adams MA (2011). The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol 300: R1288R1295.
  • Brown NJ (2005). Aldposterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235241.
  • Brunton L (2011). Goodman & Gilman's Pharmacological Basis of Therapeutics, 12th edn. p. 1224. McGraw-Hill: New York.
  • Busse R, Flemming I (1999). Nitric oxide, nitric oxide synthase and hypertensive vascular disease. Curr Hypertens Rep 1: 8895.
  • Di Francescomarino S, Sciartilli A, Di Valerio V, Di Baldassarre A, Gallina S (2009). The effect of physical exercise on endothelial function. Sports Med 39: 797812.
  • Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601605.
  • Dorrance AM, Osborn HL, Grekin R, Webb RC (2001). Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol 281: R944R950.
  • Duffy SJ, Biegelsen ES, Eberhardt RT, Kahn DF, Kingwell BA, Vita JA (2005). Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation. Hypertension 46: 707713.
  • Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL (2004). Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43: 12521257.
  • Enseleit F, Lüscher T, Ruschitzka F (2010). Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Ther Adv Cardiovasc Dis 4: 231240.
  • Francois M, Kojda G (2004). Effects of hypercholesterolemia and oxidative stress on the nitric oxide–cyclic GMP pathway. Neurochem Int 45: 955961.
  • Farquharson CA, Struthers AD (2000). Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101: 594597.
  • Farquharson CA, Struthers AD (2002). Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103: 425431.
  • Félétou M, Huang Y, Vanhoutte PM (2010). Vasoconstrictor prostanoids. Pflügers Arch 459: 941950.
  • Ferri C, Bellini C, Desideri G, Mazzocchi C, De Siati L, Santucci A (1997). Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. Clin Sci (Lond) 93: 3541.
  • Förstermann U, Pollock JS, Schmidt HH, Heller M, Murad F (1991). Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci USA 88: 17881792.
  • Fujita M, Minamino T, Asanuma H, Sanada S, Hirata A, Wakeno M et al. (2005). Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathway in hypoperfused canine hearts. Hypertension 46: 113117.
  • Furchgott RF (1988). Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte PM (ed.). Vasodilatation: Vascular Smooth Muscle, Pepties, Autonomic Nerve and Endothelium. Raven Press, Ltd: New York, pp. 401414.
  • Furchgott RF, Zawadzki JV (1980). Obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373376.
  • Gandhi SK, Ryder DH, Brown NJ (1996). Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 28: 961966.
  • Garthwaite J, Southam E, Boulton CL, Nedlsen EB, Schmidt K, Mayer B (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo]4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184188.
  • Golestaneh N, Klein C, Valmanesh F, Suarez G, Agarwal MK, Mirshahi M (2001). Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channels in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 280: 13001306.
  • Gromotowicz A, Szemaj J, Stankiewicz A, Zakrzeska A, Mantur M, Jaroszewicz E et al. (2011). Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst 12: 430439.
  • Gunaruwan P, Schmitt M, Taylor J, Lee L, Struthers A, Frenneaux M (2002). Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst 3: 123125.
  • Gunaruwan P, Schmitt M, Sharman J, Lee L, Struthers A, Frenneaux M (2005). Effects of aldosterone on forearm vasculature in treated chronic heart failure. Am J Cardiol 95: 412414.
  • Halcox JP, Nour KR, Zalos G, Quyyumi AA (2001). Coronary vasodilatation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ Res 89: 969976.
  • Hao L, Kanno Y, Fukushima R, Watanabe Y, Ishida Y, Suzuki H (2004). Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 24: 5460.
  • Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y (2006). Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol 47: 609613.
  • Heylen E, Huang A, Sun D, Kaley G (2009). Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol 54: 535542.
  • Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL (2004). Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17: 597603.
  • Imagawa K, Okayama S, Takaoka M, Kawata H, Naya N, Nakajima T et al. (2006). Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adrenocarcinoma (H295R) cells. J Cardiovasc Pharmacol 47: 133138.
  • Iwashima F, Yoshimoto T, Minami I, Sakurada M, Hirono Y, Hirata Y (2008). Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology 149: 10091014.
  • Kitagawa K, Oku N, Kimura Y, Yagita Y, Sakaguchi M, Hatazawa J et al. (2009). Relationship between cerebral blood flow and later cognitive decline in hypertensive patients with cerebral small vessel disease. Hypertens Res 32: 816820.
  • Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y et al. (2006). Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47: 671679.
  • Kusche-Vihrog K, Callies C, Fels J, Oberleithner T (2010). The epithelial sodium channel (ENaC): mediator of the aldosterone response in the vascular endothelium? Steroids 75: 544549.
  • Lalevée N, Rebsamen MC, Barrére-Lemaire S, Perrier E, Nargeot J, Bénitah JP et al. (2005). Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res 67: 216224.
  • Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE et al. (2007). Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13: 189197.
  • Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD (2003). Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 24002406.
  • Macleod MR, Johansson IM, Söderström I, Lai M, Gidö G, Weloch T et al. (2003). Mineralocorticoid receptor expression and increased survival following neuronal injury. Eur J Neurosci 17: 15491555.
  • Maeda S, Miyauchi T, Iemitsu M, Tanabe T, Goto K, Yamaguchi I et al. (2004). Endothelin receptor antagonist reverses decreased NO system in the kidney in vivo during exercise. Am J Physiol 286: E609E614.
  • Michea L, Delpiano AM, Hitschfleld C, Lobos L, Lavandero S, Marusic ET (2005). Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+ exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels. Endocrinology 146: 973980.
  • Michell BJ, Chen ZP, Tiganis T, Stapleton D, Katsis F, Power DA et al. (2001). Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 276: 1762517628.
  • Miyata K, Rahman M, Shokoji T, Nagai Y, Zhang GX, Sun GP et al. (2005). Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 29062912.
  • Moncada S, Vane JR (1981). Prostacyclin: its biosynthesis, actions, and clinical potential. Philos Trans R Soc Lond B Biol Sci 294: 305329.
  • Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109142.
  • Mutoh A, Isshiki M, Fujita T (2008). Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens Res 31: 18111820.
  • Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A et al. (2006). Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 48: 165171.
  • Nietlispach F, Julius B, Schindler R, Bernheim A, Binkert C, Kiowski W et al. (2007). Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 50: 8288.
  • Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA (2004). Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 109: 28572861.
  • Oberleithner H (2005). Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 67: 16801682.
  • Oberleithner H, Riethmüller C, Ludwig T, Hausberg M, Schillers H (2006a). Aldosterone remodels human endothelium. Acta Physiol (Oxf) 187: 305312.
  • Oberleithner H, Riethmüller C, Ludwig T, Shahin V, Stock C, Schwaab A et al. (2006b). Differential action of steroid hormones on human endothelium. J Cell Sci 119: 19261932.
  • Oberleithner H, Riethmüller C, Schillers H, MacGregor GA, de Wardener HE, Hausberg M (2007). Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA 104: 1628116286.
  • Ohmine T, Miwa Y, Takahashi-Yanaga F, Morimoto S, Maehara Y, Sasaguri T (2009). The involvement of aldosterone in cyclic stretch-mediated activation of NADPH oxidase in vascular smooth muscle cells. Hypertens Res 32: 690699.
  • Ohtani K, Usui S, Kaneko S, Takashima S, Kitano K, Yamamoto K et al. (2012). Benidipine reduces ischemia reperfusion-induced systemic oxidative stress through suppression of aldosterone production in mice. Hypertens Res 35: 287294.
  • Okamura H, Doi M, Yamaguchi Y, Fustin JM (2011). Hypertension due to loss of clock: novel insight from the molecular analysis of Cry1/Cry2-deleted mice. Curr Hypertens Rep 13: 103108.
  • Okayama S, Imagawa K, Naya N, Iwama H, Somekawa S, Kawata H et al. (2006). Blocking T-type Ca2+ channels with efonidipine decreases plasma aldosterone concentration in healthy volunteers. Hypertens Res 29: 493497.
  • Osmond J, Rigsby CS, Dorrance AM (2008). Is the mineralocorticoid receptor a potential target for stroke prevention? Clinical Sci 114: 3747.
  • Palmer RM, Ferrige AG, Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524526.
  • Park JB, Schiffrin EL (2001). ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 37: 14441449.
  • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709717.
  • Pojoga LH, Adamova Z, Kumar A, Stennett AK, Romero JR, Adler GK et al. (2010). Sensitivity of NOS-deficient vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1 deficient mice. Am J Physiol 298: H1776H1788.
  • Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL (2003). Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42: 4955.
  • Quaschning T, Ruschitzka F, Niggi B, Lunt CM, Shaw S, Wehling M et al. (2001a). Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 16: 21462151.
  • Quaschning T, Ruschitzka F, Shaw S, Lüscher TF (2001b). Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2 Part 2): 801805.
  • Rajagopalan S, Duquaine D, King S, Pitt B, Patal P (2002). Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 22122216.
  • Ramzy D, Rao V, Tumiati LC, Xu N, Sheshgiri R, Miriuka S et al. (2006). Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation 114 (1 Suppl.): 13191326.
  • Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE et al. (2010). Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 122: 958966.
  • Rigsby CS, Dorrance AM (2004). Spironolactone increases lumen diameter in the middle cerebral artery of spontaneously hypertensive stroke-prone rats (SHRSP). Hypertension 44: 536.
  • Rigsby CS, Cannady WE, Dorrance AM (2005). Aldosterone: good guy or bad guy in cerebrovascular disease? Trends Endocrinol Metab 16: 401406.
  • Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr (1998). Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451458.
  • Rodríguez-Pascual F, Busnadiego O, Lagares D, Lamas S (2011). Role of endothelin in the cardiovascular system. Pharmacol Res 63: 463472.
  • Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V (2003). Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166: 345349.
  • Rossi GP, Albertin G, Bova S, Belloni AS, Fallo F, Pagotto Trevisi L et al. (1997a). Autocrine-paracrine role of endothelin-1 in the regulation of aldosterone synthase expression and intracellular Ca2+ in human adrenocortical carcinoma NCI-H295 cells. Endocrinology 138: 44214426.
  • Rossi GP, Albertin G, Neri G, Andreis PG, Hofmann S, Pessina AC et al. (1997b). Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. J Clin Endocrinol Metab 82: 34453449.
  • Rossi GP, Carvallin M, Nussorfer GG, Pessina AC (2001). The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 38 (Suppl. 2): S49S52.
  • Rossi GP, Ganzaroli C, Cesari M, Maresca A, Plebani M, Nussdorfer GG et al. (2003). Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 57: 277283.
  • Rossier MF, Ertel EA, Vallotton MB, Capponi AM (1998). Inhibitory action of mibefradil on calcium signaling and aldosterone synthesis in bovine adrenal glomerulosa cell. J Pharmacol Exp Ther 287: 824831.
  • Rossier MF, Lesouhaitier O, Perrier E, Bockhom L, Chiappe A, Lelevée N (2003). Aldosterone regulation of T-type calcium channels. J Steroid Biochem Mol Biol 85: 383388.
  • Ruschitzka F, Quaschning T, Noll G, de Gottardi A, Rossier MF, Enseleit F et al. (2001). Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11β-hydoxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 103: 31293135.
  • Sanz-Rosa D, Oubiňa MP, Cediel E, De las Heras N, Aragoncillo P, Balfagón G et al. (2005). Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. Antioxid Redox Signal 7: 12941301.
  • Sato A, Fukuda S (2010). Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 24: 387394.
  • Schiffrin EL (2006). Effects of aldosterone on the vasculature. Hypertension 47: 312318.
  • Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A et al. (2003). Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 42: 156160.
  • Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE (2006). Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 47: 650655.
  • Schmitt M, Gunaruwan P, Frenneaux MP (2004). Rapid nongenomic aldosterone effects in the human forearm? Hypertension 43: e1.
  • Shibata S, Mu S, Kawarazaki H, Muraoka K, Ishizawa K, Yoshida S et al. (2011). Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 121: 32333243.
  • Skøtt O, Uhrenholt TR, Schjeming J, Hansen PB, Rasmussen LE, Jensen BL (2006). Rapid actions of aldosterone in vascular health and disease – friend or foe? Pharmacol Ther 111: 495507.
  • Takeda Y (2009). Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension. Hypertens Res 32: 321324.
  • Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M (2007). Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl-salt-sensitive hypertensive rats. Am J Hypertens 20: 11191124.
  • Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M (2007). Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 30: 691697.
  • Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S (2006). Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail 12: 240245.
  • Toda N (2012). Age-related changes in endothelial function and blood flow regulation. Pharmacol Ther 133: 159176.
  • Toda N, Arakawa K (2011). Salt-induced hemodynamic regulation mediated by nitric oxide. J Hypertens 29: 415424.
  • Toda N, Ayajiki K (2010). Vascular actions of nitric oxide as affected by exposure to alcohol. Alcohol Alcohol 45: 347355.
  • Toda N, Nakanishi-Toda M (2011). How mental stress affects endothelial function. Pflügers Arch Eur. J Physiol 462: 779794.
  • Toda N, Okamura T (2012). Cerebral blood flow regulation by nitric oxide in Alzheimer's disease. J Alzheimer Dis 32: 569578.
  • Toda N, Toda H (2010). Nitric oxide-mediated blood flow regulation as affected by smoking and nicotine. Eur J Pharmacol 649: 113.
  • Toda N, Imamura T, Okamura T (2010). Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus. Pharmacol Ther 127: 189209.
  • Tsuchiya K, Yoshimoto T, Hirata Y (2009). Endothelial dysfunction is related to aldosterone excess and raised blood pressure. Endocr J 56: 533539.
  • Tsutamoto T, Tanaka T, Nishiyama K, Yamaji M, Kawahara C, Fujii M et al. (2009). Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 32: 670674.
  • Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR et al. (2009). Aldosterone excess or escape: treating resistant hypertension. J Clin Hypertens (Greenwich) 11: 245252.
  • Uhrenholt TR, Schjerning J, Hansen PB, inline image R, Jensen BL, Sorensen GL et al. (2003). Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 12581266.
  • Uhrenholt TR, Schjerning J, Rasmussen LE, Hansen PB, inline image R, Jensen BL et al. (2004). Rapid non-genomic effects of aldosterone on rodent vascular function. Acta Physiol Scand 181: 415419.
  • Verhovez A, Zeoli A, Williams TA, Morello F, Brizzi MF, Veglio F et al. (2008). Primary aldosteronism (PA) and endothelial progenitor cell (EPC) bioavailability. Clin Endocrinol (Oxf) 69: 528534.
  • Virdis A, Naves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL (2002). Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40: 504510.
  • Wedgwood S, Black SM (2005). Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol 288: L480L487.
  • White K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lammer B (2003). Effects of the endothelin a receptor antagonist darusentan on blood pressure and vascular contractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 41: 890896.
  • Wong S, Brennan FE, Young MJ, Fuller PJ, Cole TJ (2007). A direct effect of aldosterone on endothelkin-1 gene expression in vivo. Endocrinology 148: 15111517.
  • Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y et al. (2011). High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 34: 7478.
  • Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988). A Novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411415.